- /
- Supported exchanges
- / US
- / SGIOY.PINK
Shionogi & Co Ltd ADR (SGIOY PINK) stock market data APIs
Shionogi & Co Ltd ADR Financial Data Overview
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Shionogi & Co Ltd ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Shionogi & Co Ltd ADR data using free add-ons & libraries
Get Shionogi & Co Ltd ADR Fundamental Data
Shionogi & Co Ltd ADR Fundamental data includes:
- Net Revenue: 465 384 M
- EBITDA: 199 035 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-29
- EPS/Forecast: 0.1891
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shionogi & Co Ltd ADR News
New
SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks ...
Assessing Shionogi (TSE:4507) Valuation After Strong Recent Share Price Returns
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. What recent returns suggest...
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an en...
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotiviba...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.